<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146341</url>
  </required_header>
  <id_info>
    <org_study_id>502.472</org_study_id>
    <nct_id>NCT00146341</nct_id>
  </id_info>
  <brief_title>Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg</brief_title>
  <official_title>An Eight Week Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg to Telmisartan 80mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80mg.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To demonstrate that a fixed dose combination of telmisartan 80 mg plus HCTZ 12.5 mg is&#xD;
      superior to telmisartan 80 mg alone in patients, who fail to respond adequately to&#xD;
      telmisartan 80 mg monotherapy, in lowering seated trough diastolic blood pressure after eight&#xD;
      weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, prospective, randomized, double-blind, parallel-group study in&#xD;
      approximately 244 patients with a history of mild-to-moderate hypertensive who have been&#xD;
      shown not to respond to telmisartan monotherapy.&#xD;
&#xD;
      All patients will enter a one-week screening phase prior to starting the eight-week&#xD;
      open-label T80 mg period. At the end of four weeks, only patients who fail to respond to T80&#xD;
      mg (DBP &gt;= 90 mm Hg) will continue the treatment with T80 mg for another four weeks. At the&#xD;
      end of eight weeks, only patients who fail to respond to T80 mg (DBP &gt;= 90 mm Hg) will be&#xD;
      randomized, double-blind, to receive either T80 mg alone or the fixed dose combination of T80&#xD;
      mg plus HCTZ 12.5 mg for eight weeks. Seated BP will be taken 24 hours post-dose at each&#xD;
      visit. Labs, ECG, and physical examination will be done at screening, at baseline and at the&#xD;
      final visit.&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      The primary objective of the study, showing that fixed dose combination is superior to&#xD;
      telmisartan 80 mg alone will be tested using the hypotheses given below.&#xD;
&#xD;
      H0: u T80/H12.5 - uT80 = 0 mm Hg versus H1: uT80/H12.5 - uT80 not equal 0 mm Hg, where&#xD;
      uT80/H12.5 anduT80 represent the average reduction from baseline (Visit 4) in trough seated&#xD;
      DBP for the fixed dose combination and telmisartan 80 mg, respectively.&#xD;
&#xD;
      Testing of the null hypothesis will be performed using a two-sided test of significance at an&#xD;
      a-level (type-I error rate) of 0.05.&#xD;
&#xD;
      Comparison(s):&#xD;
&#xD;
      The primary efficacy endpoint will be the change from baseline in seated DBP 24 hours&#xD;
      post-dose at the last visit during the double-blind treatment phase. The pre-dose measurement&#xD;
      on visit 4 will be viewed as the baseline measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy variable is change from baseline in seated DBP at trough (24 hours post-dosing) after eight weeks of randomized treatment or at last trough observation during the double-blind phase (i.e. last trough observation carried forward).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in seated SBP, standing DBP and SBP at trough after eight weeks of randomized treatment or at last trough observation during the double-blind phase. The percentage of patients responding to the treatment. Safety.</measure>
  </secondary_outcome>
  <enrollment type="Actual">345</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/HCTZ</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of mild-to-moderate hypertension defined by a mean seated DBP &gt;=95 and &lt;= 109&#xD;
             mmHg before inclusion in the open-label phase&#xD;
&#xD;
          2. Patients who fail to respond adequately to telmisartan monotherapy (mean seated DBP &gt;=&#xD;
             90 mmHg)&#xD;
&#xD;
          3. Participants between 18 and 80 years of age&#xD;
&#xD;
          4. Ability to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients taking more than three anti-hypertensive medications at the screening visit.&#xD;
&#xD;
          2. Pre-menopausal women (last menstruation 1 year prior to start of screening):&#xD;
&#xD;
               -  Who are not surgically sterile (hysterectomy, tubal ligation)&#xD;
&#xD;
               -  Who are NOT practicing acceptable means of birth control or who do NOT plan to&#xD;
                  continue using an acceptable method throughout the study (acceptable methods of&#xD;
                  birth control include IUD, oral, implantable or injectable contraceptives)&#xD;
&#xD;
          3. Any woman:&#xD;
&#xD;
               -  Who has a positive urine pregnancy test at screening (Visit 1)&#xD;
&#xD;
               -  Who is nursing&#xD;
&#xD;
          4. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:&#xD;
&#xD;
               -  SGPT(ALT) or SGOT(AST) greater than two times the upper limit of normal&#xD;
&#xD;
               -  Serum creatinine &gt; 3.0 mg/dL (or 265 mol/L) or creatinine clearance &lt; 0.6 ml/sec&#xD;
&#xD;
          5. Clinically relevant hypokalaemia or hyperkalaemia&#xD;
&#xD;
          6. Uncorrected volume depletion&#xD;
&#xD;
          7. Uncorrected sodium depletion&#xD;
&#xD;
          8. Primary aldosteronism&#xD;
&#xD;
          9. Hereditary fructose intolerance&#xD;
&#xD;
         10. Biliary obstructive disorders, cholestasis or moderate to severe hepatic insufficiency&#xD;
&#xD;
         11. Known or suspected secondary hypertension&#xD;
&#xD;
         12. Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney;&#xD;
             post-renal transplant patients, presence of only one functioning kidney&#xD;
&#xD;
         13. Congestive heart failure (NYHA functional class CHF III-IV)&#xD;
&#xD;
         14. Unstable angina within the past three months&#xD;
&#xD;
         15. Stroke within the past six months&#xD;
&#xD;
         16. Myocardial infarction or cardiac surgery within the past three months&#xD;
&#xD;
         17. PTCA within the past three months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No. 1 Hospital Affiliated Nanjing</name>
      <address>
        <city>Nanjing</city>
        <zip>210006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>254 PLA Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300150</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Hospital Affiliated to Tianjin Med University</name>
      <address>
        <city>Tianjin</city>
        <zip>300211</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No. 1 Hosp Affiliated to Med College</name>
      <address>
        <city>Zhejiang Province</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.472_U07-3558.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/24493330</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 5, 2005</study_first_submitted>
  <study_first_submitted_qc>September 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

